40
Participants
Start Date
December 7, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Tipifarnib
Oral administration
Alpelisib
Oral administration
Memorial Sloan Kettering Cancer Center, New York
UPMC Hillman Cancer Center, Pittsburgh
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center), Baltimore
Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center), Baltimore
Lake Nona DDU (Florida Cancer Specialists), Orlando
University of Wisconsin Carbone Cancer Center, Madison
Washington University, School of Medicine, St Louis
UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center), Dallas
University of Texas MD Anderson Cancer Center, Houston
City of Hope Comprehensive Cancer Center, Duarte
Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center), Boston
Lead Sponsor
Kura Oncology, Inc.
INDUSTRY